Portola Pharmaceuticals (NASDAQ:PTLA) – Equities research analysts at Oppenheimer lowered their FY2020 earnings estimates for shares of Portola Pharmaceuticals in a report issued on Tuesday, March 13th, Zacks Investment Research reports. Oppenheimer analyst J. Olson now anticipates that the biopharmaceutical company will earn $2.59 per share for the year, down from their previous estimate of $2.66. Oppenheimer has a “Buy” rating on the stock. Oppenheimer also issued estimates for Portola Pharmaceuticals’ FY2021 earnings at $4.03 EPS and FY2022 earnings at $5.67 EPS.
A number of other equities research analysts have also commented on the company. William Blair reiterated a “buy” rating on shares of Portola Pharmaceuticals in a research report on Thursday, March 1st. Citigroup reiterated a “buy” rating and issued a $74.00 price target on shares of Portola Pharmaceuticals in a research report on Thursday, December 28th. Morgan Stanley lowered Portola Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $65.00 price target on the stock. in a research report on Thursday, March 1st. Zacks Investment Research upgraded Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, ValuEngine upgraded Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $67.14.
PTLA traded down $1.29 on Thursday, reaching $30.91. The stock had a trading volume of 706,040 shares, compared to its average volume of 1,248,273. Portola Pharmaceuticals has a fifty-two week low of $30.10 and a fifty-two week high of $67.10. The company has a quick ratio of 5.92, a current ratio of 5.94 and a debt-to-equity ratio of 0.30. The stock has a market cap of $2,021.27, a PE ratio of -6.43 and a beta of 1.49.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.46) by $0.05. Portola Pharmaceuticals had a negative return on equity of 108.43% and a negative net margin of 1,268.34%. The business had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $3.71 million. During the same quarter in the prior year, the firm earned ($0.95) EPS. The business’s revenue for the quarter was down 28.4% compared to the same quarter last year.
Several institutional investors have recently made changes to their positions in the stock. Penbrook Management LLC bought a new stake in shares of Portola Pharmaceuticals during the 4th quarter valued at about $209,000. Xact Kapitalforvaltning AB bought a new stake in shares of Portola Pharmaceuticals during the 4th quarter valued at about $355,000. MetLife Investment Advisors LLC bought a new stake in shares of Portola Pharmaceuticals during the 4th quarter valued at about $1,247,000. Endurant Capital Management LP boosted its position in shares of Portola Pharmaceuticals by 7.2% during the 4th quarter. Endurant Capital Management LP now owns 107,600 shares of the biopharmaceutical company’s stock valued at $5,238,000 after purchasing an additional 7,200 shares in the last quarter. Finally, Kazazian Asset Management LLC boosted its position in shares of Portola Pharmaceuticals by 11.6% during the 4th quarter. Kazazian Asset Management LLC now owns 13,657 shares of the biopharmaceutical company’s stock valued at $665,000 after purchasing an additional 1,416 shares in the last quarter. Institutional investors own 88.44% of the company’s stock.
In related news, EVP Tao Fu sold 1,135 shares of the company’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $38.47, for a total transaction of $43,663.45. Following the sale, the executive vice president now owns 18,346 shares in the company, valued at approximately $705,770.62. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.50% of the stock is owned by corporate insiders.
WARNING: “Oppenheimer Comments on Portola Pharmaceuticals’ FY2020 Earnings (PTLA)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/oppenheimer-weighs-in-on-portola-pharmaceuticals-incs-fy2020-earnings-ptla.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.
Get a free copy of the Zacks research report on Portola Pharmaceuticals (PTLA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.